etienne maffli swiss institute for the prevention of alcohol and other drug problems
DESCRIPTION
Characteristics of male and female outpatients with drug-related problems: The situation in Switzerland between 1995 and 2003. Etienne Maffli Swiss Institute for the Prevention of Alcohol and other Drug Problems Lausanne, Switzerland. Data. - PowerPoint PPT PresentationTRANSCRIPT
Etienne Maffli
Swiss Institute for the Prevention of Alcoholand other Drug Problems
Lausanne, Switzerland
Characteristics of male and female outpatients
with drug-related problems: The situation in Switzerland
between 1995 and 2003
Data13’585 treatment episodes monitored by SAMBAD between 1995 and 2003 (survey at intake)
(statistics of the ambulatory services for alcohol or drug problems in Switzerland)
• Admissions with opiates, cocaine, stimulants, benzodiazepines, hallucinogens, inhalants or cannabis as main substance of abuse
• Centralised methadone programs and heroin prescription programmes not included
• Inpatients programmes not included
• Free participation of the services
Registered clients at intake
465
688
901969
1083
1368
1622
1420
1252
157269310
405441564621561
489
0
200
400
600
800
1000
1200
1400
1600
1800
1995 1996 1997 1998 1999 2000 2001 2002 2003
male (N=9768) female (N=3817)
N
0
1020
30
40
1995 1996 1997 1998 1999 2000 2001 2002 2003
%
Proportion of female clients in %
28.9 29.525.6
28.1 25.228.1 28.3 27.7 29.2
(overall proportion: 28.1%)
Primary drug: opiates and cocaine
0
10
20
30
40
50
60
70
80
90
100
1995 1996 1997 1998 1999 2000 2001 2002 2003
opiates (male) opiates (female) cocaine (female) cocaine (male)
%
opiates
cocaine
F
M
FM
(male: N=9768; female: N=3817)
Primary drug: cannabis and benzodiazepines
0
10
20
30
40
50
60
70
80
90
100
1995 1996 1997 1998 1999 2000 2001 2002 2003
cannabis (male) cannabis (female) benzos (male) benzos (female)
%
cannabis
benzosF
M
MF
(male: N=9768; female: N=3817)
Primary drug: hallucinogens and stimulants
0
10
20
30
40
50
60
70
80
90
100
1995 1996 1997 1998 1999 2000 2001 2002 2003
hallucinogens (male) hallucinogens (female)
stimulants (female) stimulants (male)
%
hallucinogensstimulants
F
FMM
(male: N=9768; female: N=3817)
Mean age at intake
30.530.3
27.3
28.7
27.9
2726.8
2626.3
29.5
28.728.3
28.6
28.6
28.128
27.6
27
25
26
27
28
29
30
31
32
1995 1996 1997 1998 1999 2000 2001 2002 2003
mean age (female) mean age (male)
age
N=3565 N=9290
Living status (with whom)(1995-2003)
10.9
4.8
8
21.9
5.9
24.5
23.9
12.6
5.1
5.9
15.2
29.4
31.5
0.2
0 10 20 30 40
other
with friends
with partner and child(ren)
with partner (alone)
alone with child
with parents
alone
female (N=3745) male (N=9522)
%
Living status (where)(1995-2003)
6.9
6.6
86.5
8.0
8.2
83.9
0 20 40 60 80 100
in institutions
unstableaccommodation
stableaccommodation
female (N=3742) male (N=9569)
%
Nationality(1995-2003)
4.2
15
80.8
8.8
22.2
69.1
0 20 40 60 80 100
other
EU
swiss
female (N=3707) male (N=9478)
%
4.7
43.0
47.7
4.5
6.0
51.8
38.8
3.4
0 10 20 30 40 50 60
higher level
secondary level
primary level
nevercompleted
primary school
female (N=3479) male (N=8985)
%
Highest educational level completed(1995-2003)
Labor status: regular employment and training
0
5
10
15
20
25
30
35
40
45
50
1995 1996 1997 1998 1999 2000 2001 2002 2003
regular employment (male) regular employment (female)
pupil/student (female) pupil/student (male)
%
regular employment
pupil/student
F
F
M
M
(male: N=9582; female: N=3735)
Labor status: unemployment and economical inactivity
0
5
10
15
20
25
30
35
40
45
50
1995 1996 1997 1998 1999 2000 2001 2002 2003
unemployed (male) unemployed (female)
econ. inactive (female) econ. inactive (male)
%
economical inactivity
unemployed
M
F
F
M
(male: N=9582; female: N=3735)
Source of referral (1995-2003)
6
5.1
7.9
9.4
10.4
9.9
22.3
64.8
6.3
9.6
6.6
6.2
8.9
22
66.2
9.8
0 20 40 60 80
other
court / probation / police
social services
hospital / other medical source
general practitioner
other centre
family / friends
self-referred
female (N=3817) male (N=9768)
%
multiple responses allowed
Ever previously treated
60.362.158.466.4
69 70.1
66.366.7
66.7
57.860.862.1
68.967.4
65.8
69.6
67.567.3
0
10
20
30
40
50
60
70
80
1995 1996 1997 1998 1999 2000 2001 2002 2003
female (N=3672) male (N=9374)
%
Already receiving substitutional treatment
29.728.2
34.437.236.337.8
32.5
37.4
27.32525.3
31.7
37.1
32.131.429.8
37.2
28.6
0
5
10
15
20
25
30
35
40
45
50
1995 1996 1997 1998 1999 2000 2001 2002 2003
female male
%
(male: N=9095; female: N=3593)
Daily use of primary drug (1995-2003)
47.9
14.3
79.3
7.3
33
78
54.8
14.3
87.8
14.6
78.5
33.2
0 20 40 60 80 100
cannabis(N=867;265)
hallucinogens(N=7;7)
benzodiazepines(N=172;174)
stimulants(N=82;55)
cocaine(N=560;221)
opiates(N=5603;2163)
female male%
Age at first use of primary drug(1995-2003)
20.221.3
18.5
23.7
15
19.421.2
18.1
25.6
14.7
0
5
10
15
20
25
30
opiates(N=5823;2218)
cocaine(N=658;243)
stimulants(N=98;61)
benzodiazepines(N=148;143)
cannabis(N=861;261)
male female
mean age
Secondary drugs of clients with opiates as primary drug (1995-2003)
1.1
0.5
10.6
7.3
22.1
21.8
41.1
41.9
0.7
1
11.2
10.4
27.2
43
50.2
20.0
0 10 20 30 40 50 60
other
inhalants
stimulants
hallucinogens
benzodiazepines
alcohol
cocaine
cannabis
female (N=2799) male (N=7348)%
Multiple responses allowed
Secondary drugs of clients with cannabis as primary drug (1995-2003)
1.9
0.3
3.0
6
10.2
8.8
12.1
25.8
0.9
0.9
1.5
8.2
10.5
11.6
26.9
9.2
0 10 20 30 40 50 60
other
inhalants
benzodiazepines
hallucinogens
opiates
cocaine
stimulants
alcohol
female (N=364) male (N=1162)%
Multiple responses allowed
Secondary drugs of clients with cocaine as primary drug (1995-2003)
2.3
1.6
12.7
21.2
19.2
29
46.6
54.1
1.2
1.1
12.4
14.6
37.2
49.5
49.3
21.6
0 10 20 30 40 50 60
other
inhalants
hallucinogens
benzodiazepines
stimulants
alcohol
cannabis
opiates
female (N=307) male (N=893)%
Multiple responses allowed
Secondary drugs of clients with benzodiazepines as primary drug
(1995-2003)
8.6
0
1.6
3.3
10.7
19.3
38.7
29.6
1.5
0.5
5.3
5.3
33
44.2
58.3
25.2
0 10 20 30 40 50 60
other
inhalants
hallucinogens
stimulants
cocaine
cannabis
alcohol
opiates
female (N=243) male (N=206)%
Multiple responses allowed
Currently injecting drugs(past 30 days prior intake)
27.4
23.919.924.2
4037.7 38.3
30.7
35.9
21.422.822.3
30.531.732.1
36.736.635.5
0
10
20
30
40
50
60
1995 1996 1997 1998 1999 2000 2001 2002 2003
female (N=3453) male (N=8651)
%
Opiates or cocaine as primary drug: Injecting as usual route of administration
51.151.7
41.5
40.8
51.8 53.5 51.7 50.253.8
38.3
43.841.4
47.148.7
44.5
49.648.147.5
0
10
20
30
40
50
60
1995 1996 1997 1998 1999 2000 2001 2002 2003
female (N=2639) male (N=6838)
%
Conclusions
• The proportion of female clients (28%) is quite lower than that of male clients and remains stable over time
• Both educational level and socio-economical status are generally less favorable among female clients
• Female clients are more often living with partners and/or children than male clients
• Broadly similar patterns of substance use and route of administration prior treatment intake are observed among male and female clients
• The profile of male and female clients seeking help for benzodiazepine-related problems seems to differ, suggesting a different etiology